An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
作者信息
Afzal Muhammad Zubair, Dragnev Konstantin H, Shirai Keisuke
机构信息
Hospital Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Department of Hematology-Oncology, One Medical Center Dr., Lebanon, NH, USA.
出版信息
Ann Transl Med. 2019 Mar;7(Suppl 1):S53. doi: 10.21037/atm.2019.03.09.
Abstract
摘要
相似文献
1
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
Ann Transl Med. 2019 Mar;7(Suppl 1):S53. doi: 10.21037/atm.2019.03.09.
2
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
3
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2020 Mar;21(3):387-397. doi: 10.1016/S1470-2045(19)30801-0. Epub 2020 Feb 6.
4
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Lung Cancer. 2018 Nov;125:273-281. doi: 10.1016/j.lungcan.2018.08.019. Epub 2018 Aug 25.
5
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21.
6
Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer.
Oncotarget. 2017 Sep 23;8(49):86384-86394. doi: 10.18632/oncotarget.21186. eCollection 2017 Oct 17.
7
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.
8
9
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Respir Investig. 2020 Jul;58(4):269-274. doi: 10.1016/j.resinv.2019.12.008. Epub 2020 Feb 26.
10
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Eur J Cancer. 2016 May;58:30-7. doi: 10.1016/j.ejca.2016.01.013. Epub 2016 Feb 27.
引用本文的文献
1
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges.
Breathe (Sheff). 2022 Dec;18(4):220147. doi: 10.1183/20734735.0147-2022. Epub 2023 Jan 10.
2
Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Thorac Cancer. 2022 Feb;13(3):322-337. doi: 10.1111/1759-7714.14244. Epub 2021 Dec 14.
3
Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors.
Transl Lung Cancer Res. 2020 Aug;9(4):1053-1066. doi: 10.21037/tlcr-19-396.
4
Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review.
Transl Lung Cancer Res. 2020 Apr;9(2):379-388. doi: 10.21037/tlcr.2020.03.05.
5
Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
Transl Lung Cancer Res. 2020 Apr;9(2):188-203. doi: 10.21037/tlcr.2020.02.14.
本文引用的文献
1
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
2
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21.
3
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
J Thorac Dis. 2018 Jun;10(6):3575-3584. doi: 10.21037/jtd.2018.06.08.
4
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
5
Mechanisms of resistance to immune checkpoint inhibitors.
Br J Cancer. 2018 Jan;118(1):9-16. doi: 10.1038/bjc.2017.434. Epub 2018 Jan 2.
6
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
7
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
8
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
9
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Cancer Sci. 2016 Nov;107(11):1563-1571. doi: 10.1111/cas.13072.
10
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.
Zotero 插件